Core Viewpoint - Equity Residential (NYSE:EQR) is identified as one of the best depressed stocks to buy currently, with varying analyst ratings and price targets reflecting differing outlooks for the company and the broader real estate investment trust (REIT) sector [1][3]. Group 1: Analyst Ratings and Price Targets - Barclays analyst Richard Hightower raised the price target for Equity Residential to $78 from $77 while maintaining an "Overweight" rating, indicating a positive outlook for the company [1]. - Conversely, BMO Capital downgraded Equity Residential's stock to "Market Perform" from "Outperform," with a reduced price target of $68, down from $70, reflecting concerns about the company's fundamentals in key coastal markets [3]. - Barclays has a neutral stance on overall REITs for 2026, indicating a cautious approach towards the sector despite the positive outlook for apartments, storage, and single-family rentals [2]. Group 2: Market Conditions and Company Fundamentals - The outlook for Equity Residential is influenced by a lackluster job market and stretched affordability, which are expected to soften the company's fundamentals in its key coastal markets [3]. - The company owns and manages rental properties in dynamic metro areas across the US, positioning it within a competitive real estate landscape [4].

Group 1 - Novo Nordisk A/S (NYSE:NVO) received FDA approval for its weight loss pill, leading to a share price increase of over 7% [2] - The weight loss pill represents a significant achievement for Novo Nordisk, as it has been trailing behind Eli Lilly in the weight loss drug market [2] - BMO Capital has reiterated a Market Perform rating for Novo Nordisk with a price target of $46, highlighting the potential first-mover advantage in the weight loss treatment space [2] Group 2 - Concerns were raised by Jim Cramer regarding potential hesitance from doctors to recommend Novo Nordisk's pill over Eli Lilly's weight loss drug [2] - At the JPMorgan Healthcare Conference, Novo Nordisk's CEO indicated that up to 1.5 million users might be utilizing compounded weight loss drugs due to their lower cost [2] - Jim Cramer noted the competitive landscape between Novo Nordisk and Eli Lilly, emphasizing the challenges faced by Novo Nordisk in the current market [3]

Core Viewpoint - The article discusses recent initiations of coverage by various financial institutions on several companies, highlighting their ratings and price targets, as well as the strategic insights behind these ratings. Group 1: Netflix (NFLX) - HSBC initiated coverage with a Buy rating and a price target of $107, citing Netflix's acquisitions as a response to challenges in a maturing video streaming industry, and labeling it the "undisputed global streaming leader" [1]. Group 2: Medline (MDLN) - Barclays initiated coverage with an Overweight rating and a price target of $50, emphasizing the company's scale, private-label differentiation, and logistics capabilities. Multiple firms including Wolfe Research, JPMorgan, and Goldman Sachs also started coverage with Buy-equivalent ratings, while Deutsche Bank and Wells Fargo initiated with Neutral-equivalent ratings [1]. Group 3: Andersen Group (ANDG) - Baird initiated coverage with an Outperform rating and a price target of $40, describing the company as a "highly differentiated premium provider" of tax, valuation, and advisory services. UBS and Deutsche Bank also initiated with Buy-equivalent ratings, while Morgan Stanley and Wells Fargo provided Neutral-equivalent ratings [1]. Group 4: Rocket Companies (RKT) - JPMorgan reinstated coverage with a Neutral rating and a price target of $24, expressing a constructive view on the company's new strategy but suggesting that investors may have already priced in lower rate scenarios and market share gains from acquisitions [1]. Group 5: Hims & Hers (HIMS) - Evercore ISI initiated coverage with an In Line rating and a price target of $33, viewing the current valuation as "reasonable" while noting that the market may be underestimating the durability and diversity of Hims' core platform [1].

Core Viewpoint - Vistra Corp. is recognized as one of the top 10 stocks to buy on the NYSE according to analysts, following its announcement of acquiring Cogentrix Energy for approximately $4 billion [1]. Group 1: Acquisition Details - The acquisition includes 10 modern natural gas generation facilities with a total capacity of around 5,500 megawatts [2]. - The deal is expected to close in mid-to-late 2026 [2]. Group 2: Financial Projections - BMO Capital has raised its adjusted EBITDA forecasts for Vistra Corp. to $8.204 billion in 2027, $8.334 billion in 2028, and $8.510 billion in 2029 [2]. - KeyBanc anticipates the transaction will deliver mid-single-digit accretion in 2027, with average accretion reaching high-single-digit levels from 2027 to 2029 [3]. Group 3: Analyst Ratings - BMO Capital reduced its price target for Vistra Corp. from $245 to $230 but maintained an Outperform rating [1]. - KeyBanc reaffirmed its Overweight rating on Vistra Corp. with a price target of $217 following the acquisition announcement [3]. Group 4: Company Overview - Vistra Corp. operates as a retail electricity and power generation company, serving customers, businesses, and communities with a diverse portfolio that includes natural gas, nuclear, coal, solar, and battery energy storage facilities [4].

Group 1 - Vistra Corp. is being closely monitored by analysts as a notable AI stock, with BMO Capital lowering its price target to $230.00 from $245.00 while maintaining an "Outperform" rating [1] - The company has agreed to acquire Cogentrix Energy, which includes 10 natural gas-fired power plants, for approximately $4.7 billion to address increasing power demand [2] - The acquisition deal consists of $2.3 billion in cash, around $0.9 billion in Vistra stock priced at $185 per share, and the assumption of about $1.5 billion in Cogentrix debt, net of expected tax benefits with an estimated NPV of $0.7 billion [3] Group 2 - Vistra expects the acquisition to close between mid to late 2026, and has revised its adjusted EBITDA estimates for 2027-2030, projecting figures of $8,204 billion, $8,334 billion, and $8,510 billion, along with free cash flow estimates of $4,814 billion, $5,027 billion, and $5,245 billion [4]

Core Viewpoint - Union Pacific Corporation has experienced a downgrade in its stock rating from "Outperform" to "Market Perform" by BMO Capital, reflecting a shift in market sentiment towards the company [1][6]. Group 1: Stake Changes by Institutional Investors - GAM Holding AG significantly reduced its stake in Union Pacific by 90% during the third quarter, selling 9,262 shares and retaining only 1,025 shares valued at $242,000, which may have influenced the downgrade decision [2]. - Generali Asset Management SPA SGR also reduced its stake in Union Pacific by 20.9% during the third quarter, selling 11,698 shares [3]. - Conversely, SJS Investment Consulting Inc. dramatically increased its stake by 852.4%, and CBIZ Investment Advisory Services LLC increased its holdings by 1,400% in the first quarter, indicating mixed investor sentiment [3]. Group 2: Upcoming Financial Results - Union Pacific is set to release its fourth-quarter 2025 financial results on January 27, 2026, with management discussing these results in a conference call and live webcast, which may provide further insights into the company's performance and future prospects [4][6]. Group 3: Current Stock Performance - Union Pacific's stock is currently priced at $233.62, with a market capitalization of approximately $138.57 billion, having experienced a 0.71% increase today and fluctuating between $231.20 and $234.28 [5]. - Over the past year, the stock has seen a high of $256.84 and a low of $204.66, indicating some volatility in its performance [5].

Group 1 - BMO Capital reiterated a Market Perform rating and a price target of $710 on Meta Platforms (META) following the announcement of the acquisition of AI agent startup Manus for approximately $2 billion [1] - Manus achieved a remarkable growth from $0 to $100 million in annual recurring revenue (ARR) within eight months, highlighting its effective monetization of AI [1] - The acquisition is expected to provide an incremental positive impact on Meta's projected $121 billion AI expenditure for 2026, which has not yet yielded the immediate return on investment seen by other hyperscalers [1]

Amazon.com, Inc. (NASDAQ:AMZN) is among the 14 Best S&P 500 Stocks to Buy Now. On December 17, Wells Fargo analyst Ken Gawrelski maintained an Overweight rating on the stock with a price target of $295. This is a reaffirmation of the firm’s earlier update on December 2. Wells Fargo Reiterates Overweight Rating on Amazon.com, Inc. (AMZN) This follows BMO Capital’s adjustment a day earlier when it lifted the price target on the stock to $304 from $300, while keeping an Outperform rating on the shares. The ...

Core Insights - The healthcare sector is highlighted as a promising investment opportunity heading into 2026, with many stocks remaining undervalued despite the sector's resilience and growth since the pandemic [1][2][3]. Group 1: Market Outlook - JPMorgan has upgraded the healthcare sector to a preferred investment area, citing easing policy overhang, clarity in earnings, and increased M&A activity as key factors for this positive outlook [2][3]. - The strategists believe that the healthcare sector is showing signs of stabilization and renewed momentum, positioning it favorably for 2026 and beyond [3]. Group 2: Stock Selection Methodology - The list of recommended cheap healthcare stocks is based on companies with a market capitalization exceeding $2 billion, covered by three or more analysts, and showing an upside potential of over 10% with a forward P/E ratio between 8 and 15 [5]. - The top 12 companies were ranked based on their highest upside potential, with additional data on hedge fund holdings included [5][6]. Group 3: Company Highlights - **ICON Public Limited Company (NASDAQ:ICLR)**: - Upside potential of 14.87% as of December 5, 2025, with a share price of $185.87 [8]. - Maintained a 'Market Perform' rating with a price target of $175, indicating ongoing discussions about executive changes and revenue trends [8][10]. - Analysts generally rate it as a 'Buy' with a median price target of $213.50, suggesting nearly 15% upside [11]. - **Lantheus Holdings, Inc. (NASDAQ:LNTH)**: - Upside potential of 18.48% as of December 5, 2025, with a share price of $63.30 [12]. - Almost 80% of analysts rate it as a 'Buy', with a median price target of $75, indicating strong growth potential [12]. - Recent financial performance showed mixed results, with revenue exceeding estimates but diluted EPS falling short, attributed to pricing pressures and competitive dynamics [15].

Core Insights - During market turbulence, investors often seek dividend-yielding stocks, which typically have high free cash flows and offer substantial dividends [1] Company Ratings and Performance - **United Parcel Service Inc (NYSE:UPS)**: - Dividend Yield: 6.89% - Citigroup analyst Ariel Rosa maintained a Buy rating and increased the price target from $112 to $120, with an accuracy rate of 69% [7] - UBS analyst Thomas Wadewitz also maintained a Buy rating, raising the price target from $110 to $113, with an accuracy rate of 72% [7] - Recent performance: Reported better-than-expected Q3 results and provided Q4 sales guidance above estimates [7] - **Insperity Inc (NYSE:NSP)**: - Dividend Yield: 6.80% - Truist Securities analyst Tobey Sommer maintained a Hold rating but reduced the price target from $50 to $35, with an accuracy rate of 71% [7] - JP Morgan analyst Andrew Polkowitz maintained an Underweight rating, cutting the price target from $51 to $34, with an accuracy rate of 71% [7] - Recent performance: Reported worse-than-expected Q3 results and lowered FY25 adjusted EPS and GAAP EPS guidance below estimates [7] - **Robert Half Inc (NYSE:RHI)**: - Dividend Yield: 8.60% - Barclays analyst Manav Patnaik maintained an Equal-Weight rating and reduced the price target from $45 to $36, with an accuracy rate of 74% [7] - BMO Capital analyst Jeffrey Silber maintained a Market Perform rating, cutting the price target from $36 to $31, with an accuracy rate of 69% [7] - Recent performance: Posted weaker-than-expected quarterly results [7]